enVVeno Medical/$NVNO
1D1W1MYTD1Y5YMAX
About enVVeno Medical
enVVeno Medical Corp is a medical device company focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The company first developed the VenoValve, which was a surgical replacement venous valve. It is focused on its next-generation, non-surgical venous valve product, called the enVVe System which consists of the enVVe Valve, enVVe Delivery System, enVVe Nose Cone, the enVVe Delivery System Accessories, and the enVVe Crimping System. The enVVe System is designed to treat severe deep chronic venous insufficiency through a minimally invasive, catheter-based approach. It operates in a single segment, Medical Device development, located in a single geographic location, the United States.
- Ticker
- $NVNO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 33
- Headquarters
- Irvine, United States
- Website
- www.envveno.com
enVVeno Medical Metrics
BasicAdvanced
$7.3M
-
-$24.90
1.06
-
Price and volume
Market cap
$7.3M
Beta
1.06
52-week high
$13.44
52-week low
$8.67
Average daily volume
20K
Financial strength
Current ratio
11.702
Quick ratio
11.386
Long term debt to equity
0.498
Total debt to equity
2.443
Profitability
EBITDA (TTM)
-17.256
Management effectiveness
Return on assets (TTM)
-36.67%
Return on equity (TTM)
-58.53%
Valuation
Price to book
0.35
Price to tangible book (TTM)
0.35
Price to free cash flow (TTM)
-0.464
Free cash flow yield (TTM)
-215.39%
Free cash flow per share (TTM)
-23.154
Growth
Earnings per share change (TTM)
-40.52%
3-year earnings per share growth (CAGR)
-35.53%
enVVeno Medical News
AllArticlesVideos
enVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference
Accesswire2 days ago
Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care Treatments
Accesswire4 weeks ago
enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve
Accesswire4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.